Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 15/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL241179 | 0.90 | SCD (0.58) | SCDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL347895 | 0.87 | SCD (0.51) | SCD | |
| SCHEMBL243802 | 0.84 | ALOX15 (0.41) | SCDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL243859 | 0.83 | SCD (0.60) | SCDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL348023 | 0.80 | SCD (0.61) | SCDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL245706 | 0.78 | SCD (0.64) | SCDMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL245124 | 0.77 | SCD (0.76) | SCDMEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL244719 | 0.77 | SCD (0.64) | SCDMAPTMEN1KMT2A | |
| SCHEMBL243827 | 0.76 | SCD (0.62) | SCD | |
| SCHEMBL243521 | 0.76 | SCD (0.47) | SCDMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2245029-B1 | HETEROCYCLIC INHIBITORS OF STEAROYL-COA DESATURASE | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| CN-102007123-A | Heterocyclic inhibitors of stearoyl-CoA desaturase | NOVARTIS AG | 2011-04-06 | — | — | CN | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | SCD 1/4885MAPT 2947/4885MEN1 4876/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | SCD 1/4885MAPT 2947/4885MEN1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.